Monday, September 26, 2022
Tags Glenmark Pharmaceuticals Limited; Dipeptidyl Peptidase 4 inhibitor; fixed-dose combination; type 2 diabetes; Remogliflozin-Vildagliptin-Metformin

Tag: Glenmark Pharmaceuticals Limited; Dipeptidyl Peptidase 4 inhibitor; fixed-dose combination; type 2 diabetes; Remogliflozin-Vildagliptin-Metformin